167 related articles for article (PubMed ID: 34323266)
1. Targeting the 'garbage-bin' to fight cancer: HDAC6 inhibitor WT161 has an anti-tumor effect on osteosarcoma and synergistically interacts with 5-FU.
Sergi CM
Biosci Rep; 2021 Aug; 41(8):. PubMed ID: 34323266
[TBL] [Abstract][Full Text] [Related]
2. HDAC6 inhibitor WT161 performs anti-tumor effect on osteosarcoma and synergistically interacts with 5-FU.
Sun J; Wu W; Tang X; Zhang F; Ju C; Liu R; Liang Y; Yu B; Lv B; Guo Y; Zeng D; Tao X; Wang M; Zhang Z; Zhang C; Lv XB
Biosci Rep; 2021 Apr; 41(4):. PubMed ID: 33860796
[TBL] [Abstract][Full Text] [Related]
3. Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma.
Hideshima T; Qi J; Paranal RM; Tang W; Greenberg E; West N; Colling ME; Estiu G; Mazitschek R; Perry JA; Ohguchi H; Cottini F; Mimura N; Görgün G; Tai YT; Richardson PG; Carrasco RD; Wiest O; Schreiber SL; Anderson KC; Bradner JE
Proc Natl Acad Sci U S A; 2016 Nov; 113(46):13162-13167. PubMed ID: 27799547
[TBL] [Abstract][Full Text] [Related]
4. HDAC6 inhibitor WT161 induces apoptosis in retinoblastoma cells and synergistically interacts with cisplatin.
Sun J; Qian X; Zhang F; Tang X; Ju C; Liu R; Zhou R; Zhang Z; Lv XB; Zhang C; Huang G
Transl Cancer Res; 2019 Dec; 8(8):2759-2768. PubMed ID: 35117033
[TBL] [Abstract][Full Text] [Related]
5. A novel HDAC6 inhibitor Tubastatin A: Controls HDAC6-p97/VCP-mediated ubiquitination-autophagy turnover and reverses Temozolomide-induced ER stress-tolerance in GBM cells.
Li ZY; Zhang C; Zhang Y; Chen L; Chen BD; Li QZ; Zhang XJ; Li WP
Cancer Lett; 2017 Apr; 391():89-99. PubMed ID: 28131906
[TBL] [Abstract][Full Text] [Related]
6. HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.
Hideshima T; Mazitschek R; Qi J; Mimura N; Tseng JC; Kung AL; Bradner JE; Anderson KC
Oncotarget; 2017 Oct; 8(46):80109-80123. PubMed ID: 29113288
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase 6 inhibits influenza A virus release by downregulating the trafficking of viral components to the plasma membrane via its substrate, acetylated microtubules.
Husain M; Cheung CY
J Virol; 2014 Oct; 88(19):11229-39. PubMed ID: 25031336
[TBL] [Abstract][Full Text] [Related]
8. Deactylase inhibitors disrupt cellular complexes containing protein phosphatases and deacetylases.
Brush MH; Guardiola A; Connor JH; Yao TP; Shenolikar S
J Biol Chem; 2004 Feb; 279(9):7685-91. PubMed ID: 14670976
[TBL] [Abstract][Full Text] [Related]
9. The aggresome pathway as a target for therapy in hematologic malignancies.
Simms-Waldrip T; Rodriguez-Gonzalez A; Lin T; Ikeda AK; Fu C; Sakamoto KM
Mol Genet Metab; 2008 Jul; 94(3):283-6. PubMed ID: 18472289
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of HDAC6 deacetylase activity increases its binding with microtubules and suppresses microtubule dynamic instability in MCF-7 cells.
Asthana J; Kapoor S; Mohan R; Panda D
J Biol Chem; 2013 Aug; 288(31):22516-26. PubMed ID: 23798680
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.
Bali P; Pranpat M; Bradner J; Balasis M; Fiskus W; Guo F; Rocha K; Kumaraswamy S; Boyapalle S; Atadja P; Seto E; Bhalla K
J Biol Chem; 2005 Jul; 280(29):26729-34. PubMed ID: 15937340
[TBL] [Abstract][Full Text] [Related]
12. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.
Santo L; Hideshima T; Kung AL; Tseng JC; Tamang D; Yang M; Jarpe M; van Duzer JH; Mazitschek R; Ogier WC; Cirstea D; Rodig S; Eda H; Scullen T; Canavese M; Bradner J; Anderson KC; Jones SS; Raje N
Blood; 2012 Mar; 119(11):2579-89. PubMed ID: 22262760
[TBL] [Abstract][Full Text] [Related]
13. Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma.
Amengual JE; Johannet P; Lombardo M; Zullo K; Hoehn D; Bhagat G; Scotto L; Jirau-Serrano X; Radeski D; Heinen J; Jiang H; Cremers S; Zhang Y; Jones S; O'Connor OA
Clin Cancer Res; 2015 Oct; 21(20):4663-75. PubMed ID: 26116270
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of HDAC6 modifies tau inclusion body formation and impairs autophagic clearance.
Leyk J; Goldbaum O; Noack M; Richter-Landsberg C
J Mol Neurosci; 2015 Apr; 55(4):1031-46. PubMed ID: 25434725
[TBL] [Abstract][Full Text] [Related]
15. Pyridylalanine-containing hydroxamic acids as selective HDAC6 inhibitors.
Schäfer S; Saunders L; Schlimme S; Valkov V; Wagner JM; Kratz F; Sippl W; Verdin E; Jung M
ChemMedChem; 2009 Feb; 4(2):283-90. PubMed ID: 19090524
[TBL] [Abstract][Full Text] [Related]
16. HDAC6 inhibition results in tau acetylation and modulates tau phosphorylation and degradation in oligodendrocytes.
Noack M; Leyk J; Richter-Landsberg C
Glia; 2014 Apr; 62(4):535-47. PubMed ID: 24464872
[TBL] [Abstract][Full Text] [Related]
17. HDAC6-p97/VCP controlled polyubiquitin chain turnover.
Boyault C; Gilquin B; Zhang Y; Rybin V; Garman E; Meyer-Klaucke W; Matthias P; Müller CW; Khochbin S
EMBO J; 2006 Jul; 25(14):3357-66. PubMed ID: 16810319
[TBL] [Abstract][Full Text] [Related]
18. MeCP2 deficiency is associated with reduced levels of tubulin acetylation and can be restored using HDAC6 inhibitors.
Gold WA; Lacina TA; Cantrill LC; Christodoulou J
J Mol Med (Berl); 2015 Jan; 93(1):63-72. PubMed ID: 25209898
[TBL] [Abstract][Full Text] [Related]
19. Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism.
Hui KF; Chiang AK
Int J Cancer; 2014 Dec; 135(12):2950-61. PubMed ID: 24771510
[TBL] [Abstract][Full Text] [Related]
20. CG0006, a novel histone deacetylase inhibitor, induces breast cancer cell death via histone-acetylation and chaperone-disrupting pathways independent of ER status.
Kim HM; Kim CS; Lee JH; Jang SJ; Hwang JJ; Ro S; Hyun YL; Choi J
Breast Cancer Res Treat; 2011 Nov; 130(2):365-75. PubMed ID: 21184271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
